Arcus Biosciences (RCUS) Shares Outstanding (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Shares Outstanding (Entity) of $125.5 million for Q1 2026, up 18.51% year-over-year from $105.9 million in Q1 2025, and little changed quarter-over-quarter from $125.3 million in Q4 2025.
Arcus Biosciences (RCUS) Shares Outstanding (2017 - 2026) Analysis & Trends
Arcus Biosciences' Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $125.5 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 18.51% year-over-year to $125.5 million; the TTM figure through Mar 2026 stood at $125.5 million (up 18.51% YoY), while the FY2025 annual figure was $125.3 million, up 35.9% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $125.5 million, roughly flat from $125.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $125.5 million in Q1 2026, with the low at $71.6 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $90.9 million (2024), against an average of $89.6 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) climbed 0.93% in 2022, then soared 35.9% in 2025.
- Arcus Biosciences' Shares Outstanding (Entity) stood at $72.9 million in 2022, then advanced by 3.57% to $75.5 million in 2023, then rose by 22.12% to $92.2 million in 2024, then soared by 35.9% to $125.3 million in 2025, then increased by 0.16% to $125.5 million in 2026.
- Business Quant data shows RCUS's Shares Outstanding (Entity) at $125.5 million in Q1 2026, $125.3 million in Q4 2025, and $107.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 126.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.10 Mn |
| Mar 31, 2026 | 125.40 Mn |
| Dec 31, 2025 | 107.40 Mn |
| Sep 30, 2025 | 106.50 Mn |
| Jun 30, 2025 | 106.10 Mn |
| Mar 31, 2025 | 98.40 Mn |
| Dec 31, 2024 | 90.10 Mn |
| Sep 30, 2024 | 91.40 Mn |
| Jun 30, 2024 | 91.10 Mn |
| Mar 31, 2024 | 86.20 Mn |
| Dec 31, 2023 | 74.00 Mn |
| Sep 30, 2023 | 74.60 Mn |
| Jun 30, 2023 | 73.20 Mn |
| Mar 31, 2023 | 73.00 Mn |
| Dec 31, 2022 | 72.00 Mn |
| Sep 30, 2022 | 72.20 Mn |
| Jun 30, 2022 | 71.80 Mn |
| Mar 31, 2022 | 71.20 Mn |
| Dec 31, 2021 | 69.35 Mn |
| Sep 30, 2021 | 71.29 Mn |